<DOC>
	<DOCNO>NCT02759016</DOCNO>
	<brief_summary>Intravenous BI 836826 combination ibrutinib relapsed/refractory Chronic Lymphocytic Leukemia ( CLL ) patient pre-treated least one prior line systemic therapy , eligible treatment ibrutinib . Objectives trial determine recommend Phase 2 dose BI 836826 , investigate number patient complete response document safety tolerability BI 836826 give combination ibrutinib</brief_summary>
	<brief_title>Intravenous BI 836826 Combination With Ibrutinib Relapsed/Refractory Chronic Lymphocytic Leukemia ( CLL ) Patients Who Have Received Least One Prior Systemic Therapy , Who Are Eligible Treatment With Ibrutinib</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<criteria>Inclusion criterion : Diagnosis Chronic Lymphocytic Leukemia ( CLL ) establish accord International Workshop Chronic Lymphocytic Leukemia ( IWCLL ) criterion . Relapsed refractory CLL pretreated least one prior line systemic therapy CLL . Indication treatment consistent IWCLL criterion , i.e . least one follow criterion meet Evidence progressive marrow failure manifest development , worsen , anemia and/or thrombocytopenia . Massive progressive symptomatic splenomegaly . Massive node progressive symptomatic lymphadenopathy . Progressive lymphocytosis absence infection , increase blood Absolute Lymphocyte Count ( ALC ) &gt; =50 % 2month period , lymphocyte doubling time ( LDT ) &lt; 6 month ( long initial ALC &gt; =30000/µl ) . Autoimmune anemia and/or thrombocytopenia poorly responsive corticosteroid standard therapy . Constitutional symptom , define one follow diseaserelated symptom sign : unintentional weight loss 10 % within previous 6 month significant fatigue fever higher 100.5°F 38.0°C &gt; =2 week without evidence infection night sweat &gt; 1 month without evidence infection Clinically quantifiable disease burden define least one following : either ALC &gt; 10 000/µL , measurable lymphadenopathy quantifiable bone marrow infiltration document bone marrow biopsy screen Resolution clinically relevant acute nonhematologic toxic effect prior antitumor therapy resolve Grade &lt; =1 Baseline laboratory data define : Hemoglobin ( Hb ) : &gt; =8g/dL Absolute Neutrophil Count ( ANC ) : &gt; =1000/µL Platelet ( PLT ) : &gt; =25000/µL Glomerular Filtration Rate ( GFR ) Creatinine Clearance : &gt; =30ml/min Aspartate Aminotransferase ( AST ) Alanine Aminotransferase ( ALT ) : &lt; 3 x Upper Limit Normal ( ULN ) Bilirubin total : &lt; 1.5 x ULN Activated Partial Thromboplastin Time ( aPTT ) , Prothrombin Time ( PT ) International Normalized Ratio ( INR ) : &lt; =1.5 x ULN PT &lt; =1.5 x ULN , INR &lt; =1.5 Male female patient . Women childbearing potential must agree use highly effective method birth control trial least 1 year last dose BI 836826 1 month last dose ibrutinib . Eastern Cooperative Oncology Group ( ECOG ) performance score 0 2 . Age 18 year older Eligible able secure source ibrutinib Written Informed Consent Further Inclusion criterion apply Exclusion criterion : Known transformation Chronic Lymphocytic Leukemia ( CLL ) aggressive Bcell malignancy time screen Prior allogeneic stem cell transplant within one year active graft vs. host disease . History nonCLL malignancy except adequately treat situ , stage 1 2 carcinoma Complete Response ( CR ) , cancer CR &gt; =2 year end cancer treatment . Active , uncontrolled autoimmune cytopenia . Patients autoimmune cytopenia control corticosteroid dos &lt; =20 mg prednisolone equivalent may enrol . Previous CLL treatment CD37targeting antibody CD37antibody drug conjugate . Previous treatment ibrutinib Previous treatment another Bruton 's Tyrosine Kinase ( BTK ) inhibitor . Ongoing systemic immunosuppressive therapy corticosteroid . Active bacterial , viral , fungal infection require systemic treatment time study entry . Human Immunodeficiency Virus ( HIV ) infection Active hepatitis B C evidence detection virus specific Deoxyribonucleic Acid ( DNA ) Ribonucleic Acid ( RNA ) . History stroke intracranial hemorrhage within 6 month prior enrollment Chronic persistent atrial flutter atrial fibrillation . Patients intermittent atrial fibrillation may enrol without episode &gt; = 6 month without indication anticoagulation Requirement chronic anticoagulation warfarin direct oral anticoagulant time screen . Chronic treatment ( i.e . &gt; 7 day ) strong Cytochrome P450 ( CYP3A ) inhibitor terminate prior first dose ibrutinib . Unstable angina pectoris , uncontrolled hypertension , uncontrolled asthma pulmonary disease Women pregnant , nursing , plan become pregnant trial Further Exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>